Subtype
Female Reproductive System Carcinoma
CI-CAN-00002685Explore in graph →
458 active trials5 approved drugs36 evidence items
- NCIt
- C181162
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002685Explore in graph →
Clinical trials
1,481 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (201)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03241745 | A Study of Nivolumab in Selected Uterine Cancer Patients | completed | Phase 2 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT02312245 | Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 13 | Mayo ClinicOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT03745950 |
| UTOLA: UTerin OLAparib(UTOLA) |
| completed |
| Phase 2 |
| 147 |
| ARCAGY/ GINECO GROUPOTHER |
| 1 |
| Dec 4, 2024 |
| clinicaltrials |
| NCT02953457 | Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation | completed | Phase 2 | 40 | Roswell Park Cancer InstituteOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03318900 | T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 5 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT02113878 | Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck | completed | Phase 1 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT02040142 | HIPEC for Peritoneal Carcinomatosis | completed | Phase 2 | 51 | Albert Einstein College of MedicineOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT02480374 | Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer | completed | Phase 1 | 18 | ImunonINDUSTRY | 1 | Oct 2, 2024 | clinicaltrials |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)(DICE) | completed | Phase 2 | 134 | Imperial College LondonOTHER | 2 | Sep 20, 2024 | clinicaltrials |
| NCT05002868 | Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors | completed | Phase 1 | 23 | Rhizen Pharmaceuticals SAINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT05700669 | Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 3 | Valerio TherapeuticsINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06599749 | Establishment and Standardization of a Platform for In-depth Tumour Profiling (TUPRO) in Patients With Advanced and Metastatic High-Grade Adenocarcinoma of Ovarian, Tubal or Peritoneal Origin (TUPRO-Gyn) | completed | — | 80 | University Hospital, Basel, SwitzerlandOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03598270 | Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer(ANITA) | completed | Phase 3 | 417 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 5 | Aug 30, 2024 | clinicaltrials |
| NCT05783167 | Self-collected Vaginal and Urine Samples in HIV-positive Women | completed | — | 502 | University of AarhusOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT01606241 | Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 24 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT01344837 | Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer | completed | — | 360 | Gynecologic Oncology GroupNETWORK | 1 | Aug 14, 2024 | clinicaltrials |
| NCT03539406 | Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients(INTRO) | completed | Phase 1 | 11 | Radboud University Medical CenterOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT04296890 | A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression(SORAYA) | completed | Phase 3 | 106 | ImmunoGen, Inc.INDUSTRY | 11 | Aug 7, 2024 | clinicaltrials |
| NCT02020707 | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers | completed | Phase 1 | 43 | Mayo ClinicOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT03602586 | Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 2 | Jul 26, 2024 | clinicaltrials |
| NCT06517433 | First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b | completed | Phase 1 | 62 | Mersana TherapeuticsINDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06517485 | First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b | completed | Phase 1 | 142 | Mersana TherapeuticsINDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT02501954 | Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol | completed | Phase 3 | 48 | Women's Cancer Care Associates, LLCOTHER | 2 | Jul 23, 2024 | clinicaltrials |
| NCT02344095 | A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer(POPOPO) | completed | Phase 1 | 12 | Seoul National University HospitalOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT04257045 | Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives | completed | — | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT03752398 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)(DUET-3) | completed | Phase 1 | 198 | Xencor, Inc.INDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
| NCT06483399 | Research on Nutritional Risk Indexes and Inflammatory Indicators in Postoperative Complications and Prognosis of Epithelial Ovarian Cancer Patients | completed | — | 1,108 | Qinglei GaoOTHER | 0 | Jul 3, 2024 | clinicaltrials |
| NCT00026663 | Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance | completed | — | 86 | National Cancer Institute (NCI)NIH | 1 | Jul 1, 2024 | clinicaltrials |
| NCT04593381 | Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer(MITO-RT3/RAD) | completed | N/A | 376 | Gemelli Molise HospitalOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT02164461 | Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer | completed | Phase 1 | 12 | Advaxis, Inc.INDUSTRY | 1 | May 20, 2024 | clinicaltrials |
| NCT03093155 | Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab | completed | Phase 2 | 78 | Yale UniversityOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT02668913 | LCC-CARIS-01: Molecular Profiling in Gynaecological Cancer | completed | N/A | 72 | Geoff HallOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT04676334 | CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib(CATCH-R) | completed | Phase 3 | 34 | pharmaand GmbHINDUSTRY | 6 | May 7, 2024 | clinicaltrials |
| NCT04972682 | [SENTRY] Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk Endometrial Cancer(SENTRY) | completed | N/A | 102 | Moscow City Oncology Hospital No. 62OTHER_GOV | 1 | May 7, 2024 | clinicaltrials |
| NCT01439490 | FES-PET to Determine ER-expression in Epithelial Ovarian Cancer | completed | Phase 2 | 15 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT02312661 | Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer(OVMET) | completed | Phase 1 | 15 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT02132858 | Genetic Mutations in Blood and Tissue Samples in Predicting Response to Treatment in Patients With Locally Advanced Rectal Cancer Undergoing Chemoradiation | completed | — | 43 | Fox Chase Cancer CenterOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT06366997 | Diagnosis of Epithelial Ovarian Cancer Using Ovarian Cancer Score (OCS) Test | completed | — | 1,352 | Chongqing University Cancer HospitalOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT02996825 | Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer | completed | Phase 1 | 44 | City of Hope Medical CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT01001910 | Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 22 | Albert Einstein College of MedicineOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT02728830 | A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers | completed | Early Phase 1 | 39 | AA SecordOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT02901899 | Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 45 | Northwestern UniversityOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03015129 | A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer | completed | Phase 2 | 80 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT05074472 | A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors | completed | Phase 1 / Phase 2 | 35 | ZielBio, Inc.INDUSTRY | 1 | Jan 29, 2024 | clinicaltrials |
| NCT04626466 | Effect of Irradiation Doses < 10 Gy and of Irradiated Bone Volume on the Variation of Blood Elements of the Complete Blood Count During and After Pelvic Irradiation(MIFADORESOL) | completed | — | 100 | Institut de cancérologie Strasbourg EuropeOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT02915523 | Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer | completed | Phase 1 / Phase 2 | 140 | Syndax PharmaceuticalsINDUSTRY | 1 | Jan 10, 2024 | clinicaltrials |
| NCT03367923 | Health and Recovery Program in Increasing Physical Activity Level in Stage IA-IIIA Endometrial Cancer Survivors | completed | Phase 2 | 47 | Stanford UniversityOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT03784677 | A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors | completed | Phase 1 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04474184 | Development of a New Early Detection Test to Reduce Racial Disparities in Endometrial Cancer (EC) Death Rates | completed | Phase 1 | 33 | Mayo ClinicOTHER | 1 | Nov 18, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Dec 27, 2024source: clinicaltrials